Zanamivir (Gmp)

CAS:139110-80-8
Zanamivir (GMP)is a neuraminidase inhibitor used in the treatment and prophylaxis of influenza caused by influenza A virus and influenza B virus . Zanamivir was the first neuraminidase inhibitor commercially developed. It is currently marketed by GlaxoSmithKline under the trade name Relenza as a powder for oral inhalation.
Simcere's Zanamivir API:
In 2006 Simcere was granted a license by GlaxoSmithKline to make products containing Zanamivir, Simcere is the only pharmaceutical company in mainland China that has such a license.
The API materials and preparations of Zanamivir are both successfully passed and received SFDA GMP certification.

Some inspection data
Properties : White or off white crystalline powder
Specific rotation : 37.7o
PH : 5.6
Chloride : 0.02% max
Total bacteria : 100 cfu/g max
Yeasts and Moulds : 10 cfu/g max
Escherichia coli : Not detected
Pseudomonas aeruginosa : Not detected
Staphylococcus aureus : Not detected
Assay : 98% Min